Condition category
Musculoskeletal Diseases
Date applied
11/12/2009
Date assigned
19/02/2010
Last edited
15/03/2010
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Mr Vittorio Marchesin

ORCID ID

Contact details

850 Maude Avenue
Mountain View
California
94043
United States of America
vmarchesin@chemocentryx.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

NCT01027728

Protocol/serial number

CL003_354

Study information

Scientific title

A randomised, double-blind, placebo-controlled, phase I/II study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis

Acronym

CARAT-1

Study hypothesis

CCX354-C is safe and well tolerated in subjects with stable rheumatoid arthritis (RA) based on subject incidence of adverse events.

As of 08/03/2010 this record was updated to include a new study site in Romania. Details of this have been added to the country of recruitment field.

Ethics approval

1. Belgium: Comite d'ethique Hospitalo-Facultaire Universitaire de Liege approved on the 30th October 2009 (ref: 2009/200)

Added 15/03/2010:
2. Romania: National Ethic Commission for the Clinical Studies of Medicine approved on the 3rd December 2009 (ref: 3243,3863)

Study design

Randomised double-blind placebo-controlled phase I/II study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Rheumatoid arthritis

Intervention

1. 100 mg CCX354-C or placebo once daily for 14 days
2. 100 mg CCX354-C or placebo twice daily for 14 days
3. 200 mg CCX354-C or placebo once daily for 14 days

Total duration of treatment: 14 days
Total duration of follow-up: 14 days

Intervention type

Drug

Phase

Phase I/II

Drug names

CCX354-C

Primary outcome measures

Subject incidence of adverse events over 14 days of dosing

Secondary outcome measures

Evaluate possible interaction with methotrexate at a number of dose levels in subjects with stable RA; pharmacokinetic (PK) measurements on Day 14 and 15.

Overall trial start date

08/12/2009

Overall trial end date

30/03/2010

Reason abandoned

Eligibility

Participant inclusion criteria

1. Male or female subjects, aged 18 - 75 years inclusive, with stable RA based on American College of Rheumatology (ACR) criteria for at least 3 months (subjects do not need to have active RA for Stage A of the study)
2. Subjects must have been on a stable dose of methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly, but not intravenously, for greater than or equal to 8 weeks prior to randomisation
3. If a subject is also taking sulfasalazine or hydroxychloroquine, the subject must have been on a stable dose of these medications for at least 8 weeks prior to randomisation
4. If a subject is on corticosteroid therapy, the dose must not exceed 10 mg prednisone or equivalent and the subject must have been on a stable dose for at least 4 weeks prior to randomisation
5. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
6. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen
7. Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments
8. Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after, any administration of study medication. Adequate contraception is defined as usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to screening, of a stable regimen of any form of hormonal contraception or an intra-uterine device. Use of abstinence alone is not considered adequate. Use of a barrier method alone is considered adequate only if the male partner was vasectomized at least six months prior to Screening. Use of a double-barrier method of contraception is acceptable.

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

24

Participant exclusion criteria

1. Diagnosed with RA prior to 16 years of age
2. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at Screening
3. History within one year prior to randomisation of illicit drug use
4. History of alcohol abuse at any time in the past
5. Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomisation
6. Use of leflunomide within 6 months of randomisation
7. Use of etanercept or anakinra within 4 weeks of randomisation
8. Use of rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomisation
9. Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant, or verapamil
10. History or presence of any form of cancer within the 10 years prior to randomisation, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
11. Evidence of tuberculosis based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.TB test performed during screening
12. Presence of Felty's syndrome, psoriatic arthritis, or other auto-immune diseases
13. Major surgery (including joint surgery) within 12 weeks prior to randomisation
14. Subject's haemoglobin is less than 11 g/dL (6.83 mmol/L) at screening
15. Subject has any evidence of hepatic disease; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin greater than 1.5 x the upper limit of normal
16. Subject has any evidence of renal impairment; serum creatinine greater than 1.5 x upper limit of normal
17. The subject had an infection requiring antibiotic treatment within 4 weeks of randomisation
18. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study
19. Participated in any clinical study of an investigational product within 30 days prior to randomisation

Recruitment start date

08/12/2009

Recruitment end date

30/03/2010

Locations

Countries of recruitment

Belgium, Romania

Trial participating centre

850 Maude Avenue
California
94043
United States of America

Sponsor information

Organisation

ChemoCentryx, Inc. (USA)

Sponsor details

850 Maude Avenue
Mountain View
California
94043
United States of America

Sponsor type

Industry

Website

http://www.chemocentryx.com

Funders

Funder type

Industry

Funder name

ChemoCentryx, Inc. (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes